MedTrace Logo

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

NCT00040183 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 569

Last updated 2018-01-10

No results posted yet for this study

Summary

The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.

Conditions

Interventions

DRUG

Tarceva (erlotinib HCl, OSI-774)

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • OSI Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-29
Primary Completion
2004-01-15
Completion
2004-01-15

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Germany
  • Greece
  • Israel
  • Italy
  • Mexico
  • New Zealand
  • Poland
  • Romania
  • Singapore
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040183 on ClinicalTrials.gov